Abstract
The Abl family of non-receptor tyrosine kinases encoded by the genes ABL1 and ABL2 are part of the signaling pathways that control cell proliferation, migration and apoptosis. The activity of Abl family kinases is tightly controlled through an autoinhibitory mechanism based on intramolecular interactions controlling the activity of the kinase domain. Activation of Abl kinases is promoted by phosphorylation by upstream kinases or engagement by interaction partners and results in a conformational modification of the kinase domain. Abl kinases are frequently deregulated in human leukemias because of chromosomal abnormalities that lead to the expression of fusion proteins such as BCRAbl1. No activating Abl mutations have been detected in solid tumors, however in many of them, increased c-Abl/Arg activity has been revealed. The reported capacity of c-Abl to promote the downregulation of the CDK inhibitors p27KIP1 and p21CIP1 in hematological as well as in solid tumors offers an explanation for the mechanism of the mitogenic effect of Abl activation.
Keywords: Abl, apoptosis, Arg, BCR-Abl1, proliferation, SH2, SH3, tyrosine-kinase-inhibitors.
Graphical Abstract
Current Enzyme Inhibition
Title:The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Volume: 13 Issue: 2
Author(s): Elisa Lupino and Marco Piccinini*
Affiliation:
- Department of Oncology, School of Medicine, University of Torino, Torino,Italy
Keywords: Abl, apoptosis, Arg, BCR-Abl1, proliferation, SH2, SH3, tyrosine-kinase-inhibitors.
Abstract: The Abl family of non-receptor tyrosine kinases encoded by the genes ABL1 and ABL2 are part of the signaling pathways that control cell proliferation, migration and apoptosis. The activity of Abl family kinases is tightly controlled through an autoinhibitory mechanism based on intramolecular interactions controlling the activity of the kinase domain. Activation of Abl kinases is promoted by phosphorylation by upstream kinases or engagement by interaction partners and results in a conformational modification of the kinase domain. Abl kinases are frequently deregulated in human leukemias because of chromosomal abnormalities that lead to the expression of fusion proteins such as BCRAbl1. No activating Abl mutations have been detected in solid tumors, however in many of them, increased c-Abl/Arg activity has been revealed. The reported capacity of c-Abl to promote the downregulation of the CDK inhibitors p27KIP1 and p21CIP1 in hematological as well as in solid tumors offers an explanation for the mechanism of the mitogenic effect of Abl activation.
Export Options
About this article
Cite this article as:
Lupino Elisa and Piccinini Marco*, The Polyhedric Abl Kinases and their Pharmacologic Inhibitors, Current Enzyme Inhibition 2017; 13 (2) . https://dx.doi.org/10.2174/1573408013666161110125325
DOI https://dx.doi.org/10.2174/1573408013666161110125325 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Recent Patents on the Identification and Clinical Application of microRNAs and Target Genes
Recent Patents on DNA & Gene Sequences CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design Viral Disorder or Disordered Viruses: Do Viral Proteins Possess Unique Features?
Protein & Peptide Letters Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design A Review on Synthesis, Anticancer and Antiviral Potentials of Pyrimidine Derivatives
Current Bioactive Compounds Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews